Lymphoma
Lymphoma
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
60
Clinical Trials
Lymphoma
NA
Accepting Patients
nct/study# NA / EURPT00000067-PT-SK
Single Patient Emergency Use IND Of PLX-PAD In Patient GDB
Learn More
Lymphoma
Phase III
Accepting Patients
nct/study# NCT01804686 / PCI32765CAN3001-EXT
A Phase 3b, Multicenter, Open-Label, PCI-32765 (Ibrutinib) Long-Term Extension Study
Learn More
Lymphoma
Phase II
Accepting Patients
nct/study# NCT02601313 / KTE-C19-102
A Phase 2 Multicenter Study Evaluating The Efficacy Of KTE-C19 In Subjects With Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
Learn More
Lymphoma
NA
Accepting Patients
nct/study# NCT03229200 / PCYC-1145-LT
Extended Treatment Protocol For Subjects Continuing To Benefit From Ibrutinib After Completion Of Ibrutinib Clinical Trials
Learn More
Lymphoma
NA
Accepting Patients
nct/study# NCT03888105 / R1979-ONC-1625-US
An Open-Label Study To Assess The Anti-Tumor Activity And Safety Of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Antibody, In Patients With Relapsed Or Refractory Follicular Lymphoma
Learn More
Lymphoma
Phase II
Accepting Patients
nct/study# NCT02742090 / TGR-1202-201
A Phase 2 Study To Assess The Safety And Efficacy Of TGR-1202 In Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant To Prior BTK (Bruton Tyrosine Kinase) Or PI3K-Delta (Phosphoinositide-3-Kinase) Inhibitor Therapy
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.